Shkreli Says Price Increases for Turing Drug Don't Matter
- Turing CEO is interviewed about costs on Bloomberg TV
- Company's drug so small `it doesn't affect the system at all'
The Politics of High Drug Prices
This article is for subscribers only.
Martin Shkreli, whose pharmaceutical company has been criticized for raising the price of a drug by more than 5,000 percent, said the increase barely causes a ripple in the health-care system.
Shkreli’s company, Turing Pharmaceuticals AG, this year raised the price of Daraprim, used by HIV and cancer patients, to $750 a pill from $13.50 a pill. The company gives away or heavily discounts the treatment for many patients, Shkreli said in an on Bloomberg TV.